The clinical investigator generally provides the communication link between the IRB and the sponsor. Such linkage is agreed to by the sponsors and investigators when they sign forms FDA-1571 and.. Copies of Form FDA 1572 with its attachments may be sent by the Sponsor-Investigator to FDA to satisfy Form FDA 1571, field 13, item 6 b-d. Information can be supplied in the form of attachments.. Sponsor-Investigator means an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. The term does.. (f) Sponsor-investigator means an individual who both initiates and actually conducts, alone or with others, a clinical investigation, i.e., under whose immediate direction the test article is.. (a) If FDA has information indicating that an investigator (including a sponsor-investigator) has repeatedly or deliberately failed to comply with the requirements of this part, part 50 or part 56..
Subpart B - Investigational New Drug Application (IND) Sec. 312.23 IND content and format. (a) A sponsor who intends to conduct a clinical investigation subject to this part shall submit an.. Sponsor-Investigator FDA would expect the sites to operate as non- IND sites. 20. 21. E6 Good Clinical Practice: Consolidated Guideline. Published as official guidance in U.S. Federal Register (May 1997 ) The objective of this ICH GCP guidance is to provide a . unified standard. for the European Union (EU), Japan, and the United States to facilitate the mutual acceptance of clinical.
Sponsor-Investigator means an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug or device is administered or dispensed. Monitor, when used as a noun, means an individual designated by a sponsor or contract research organization to oversee the progress of an investigation A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21 CFR 812. This means that such investigators hav The FDA definition of a sponsor-investigator means an individual who both initiates and actually conducts, alone or with others, an investigation, that is, under whose immediate direction the investigational device is administered, dispensed, or used. The term does not include any person other than an individual. (21 CFR 812.3 (o) The sponsor-investigator must: 1. Complete educational requirements to become knowledgeable about the additional regulatory obligations they have as the sponsor-investigator of FDA-regulated research. 2. Maintain appropriate and up-to-date IND or IDE application documentation in his/her study regulatory files. 3. Provide ORRS or the Cancer Center Compliance Office with any additional FDA OHRP FDA Assurance Oversight Engagement Sponsor/investigator roles and conduct Drug/device dev't & testing process 45 CFR 46 21 CFR 312, 812, 50, 54, 56 Subpart B: Pregnant women, Fetuses, neonates Subpart C: Prisoners Subpart D: Children Subpart E: IRB Registration Subpart A: Protection of Human Subjects
Regulatory Binder Checklist for FDA-Regulated Sponsor/ Sponsor-Investigator Studies DIRECTIONS: 1. The purpose of a regulatory binder is to assure that all essential elements are maintained in an organized fashion throughout the lifecycle of a study. These documents are essential to the quality conduct of the study. 2. As a sponsor of an IND/IDE you must keep a regulatory binder. If you are also th This may be necessary when the Sponsor-Investigator is leaving the university or no longer has the resources to fulfill Sponsor -Investigator responsibilities. In order to transfer the IND, both the new and former owners are required to submit information to the FDA. This includes a letter from the former owner stating that all rights to the application have been transferred to the new owner.
Sponsor Investigator Responsibilities . Page 1 of 3 . HSPP Use Only: Sponsor Investigator v2020-06 . Sponsor-Investigator Requirements . A sponsor-investigator is the holder of the IND and assumes all sponsor responsibilities required by the FDA of the sponsor. In addition, the sponsor-investigator is also an investigator, and is responsible for conductin g the study according to the FDA. • The FDA allows a sponsor-investigator to withdraw an IND 'without prejudice, in other words, they won't hold it against you. Withdrawing an IND means there will be no further activity, no studies, no data collection, nothing. It is possible to have the FDA withdraw the IND or you, as sponsor-investigator withdraw the IND, this typically happens if there has been no activity for a. Some of the responsibilities of the Investigator at a site include: Await FDA and IRB approval before allowing subjects to participate. 21 CRF 812.110. Be compliant with the agreement, protocol, FDA and IRB. 21 CRF 812.110. Maintain, control and supervise the use of the investigational devices. 21 CRF.100, 21 CRF 812.110 . The Food, Drug, and Cosmetic Act (FD&C Act) prohibits the failure to establish or maintain any record or make any report required under section 505(i) and the failure or refusal to comply with any requirement under 520(g). 21 U.S.C. § 331(e) The FD&C. A sponsor-investigator, on the other hand, takes on the responsibility as a clinical study sponsor and also conducts or oversees the clinical trial. Thus, a sponsor-investigator must comply with the applicable regulatory requirements that pertain to both the sponsor and the investigator. 2,3. Clinical trials: Study sponsor responsibilitie
Fda Guidance Sponsor Investigator The sponsor shall identify significant change is available, reference therein may be. Pdf version with or.. Individual investigators may meet the FDA definition of a sponsor-investigator, in which case the application process is generally less complicated than for commercial sponsors, and this review addresses only this circumstance. Filing an IND requires completion of 3 sets of forms: 1 detailing the study (FDA Form 1571), 1 providing information about the investigator and study site (FDA Form.
The IND Sponsor-Investigator must also submit form 1572 that is a formal contract with FDA to adhere to IC, IRB review, and general IND regulations. Refer to Steps 5 and 6 to Cover Letter Template and FDA Forms. 5. Prepare a Cover letter - Accompany your cover letter using the following template: IND Cover Letter Template. 6. Fill out FDA IND Applications: Form FDA 1571 (PDF - 221KB. FDA regulations provide that sponsors select principal investigators (PIs) qualified by training and experience. The regulations do not, however, provide answers for every possible contingency sponsors face in PI selection or management. FDA's Office of Good Clinical Practice responds to questions from the public interpreting FDA's position, offering advice on how to proceed and pointing. In cases where preparation of a formal IB is impractical, the sponsor-investigator should provide, as a substitute, an expanded background information section in the trial protocol that contains the minimum current information described in this guideline. 7.2 General Considerations The IB should include: 7.2.1 Title Page. This should provide the sponsor's name, the identity of each. The responsibilities of the sponsor, investigator, and other parties with respect to the use of these computerized systems should be clear, and the users should be provided with training in their use. (c) Ensure that the systems are designed to permit data changes in such a way that the data changes are documented and that there is no deletion of entered data (i.e. maintain an audit trail. FDA From 1571 page 1 Submitted with the initial IND submission and each subsequent submission to the IND FDA From 1571 page 2 The FDA has 30-days to review the protocol. FDA will not contact sponsor if all is OK to proceed, only if a hold is needed
New FDA Warning Letter Issued in COVID Drug Trial . As the severity and impact of the coronavirus increased in the United States from early 2020, many drug sponsors began to conduct trials of drug treatments for the virus. Several of these trials were not being conducted properly and lacked adherence to FDA guidelines or even approval of the. Copies of Form FDA 1572 with its attachments may be sent by the Sponsor-Investigator to FDA to satisfy Form FDA 1571, box 12, item 6 b-d. Information can be supplied in the form of attachments (such as a curriculum vitae) rather than entering that information directly onto the form, but this should be so noted under the relevant section numbers. Form FDA 3674. The Food and Drug Administration. • As Sponsor-Investigator and holder of an IND, you are required to submit reports to the FDA until the study is completed, the IND is inactivated, or is withdrawn. • Annual reports should be submitted as long as the IND is active regardless of what activity there is
VCU sponsor-investigator training is developed and managed by the FDA program manager within the OVPRI Division of Clinical Research. 3. On-demand training is offered through Talent@VCU via the Investigational New Drug Application (IND) Sponsor and Investigator Training Modules or Investigational Device Exemptions (IDEs) Sponsor and Investigator Training Modules 4. Customizable. FDA Forms 3500 and 3500A 10. Form 3674 Include the Certification of Clinicaltrials.gov registration. Keep all versions 11. Investigational Product Info. (device o nly) Include a summary document describing the ive stigat oal pr duct under tudy. Regulatory Binder Checklist for FDA-Regulated Sponsor/ Sponsor-Investigator Studies VCU Sponsor sponsor-investigator (SI). IRBs (not FDA) approve Nonsignificant Risk IDEs (NSR-IDEs) for devices that do not meet the definition of SR. - If IRB disagrees with sponsor, then IDE -> FDA. Significant Risk vs Nonsignificant Risk Devices An SR device poses a potential for serious risk to the health, safety, or welfare of a subject. A device is SR (and requires an IDE) if it: - is. [Sponsor-Investigator Name] 6.1 Investigator and Facilities Data 6.1.1 Form FDA 1572 6.1.2 Sponsor-Investigator Credentials 6.1.3 Subinvestigator(s) Credentials (CVs) 6.1.4 Disclosure of Financial Interests 6.2 Clinical Trial Registration 7 Chemistry and Manufacturing [21 CFR 312.23(a)(7)
On the application of a sponsor or sponsor-investigator, the FDA may waive any of the requirements contained in these regulations, including the requirement for IRB review, for specific research activities or for classes of research activities, otherwise covered by these regulations. 56.105 . Updating IRB Membership. DHHS requires that the Institution submit IRB membership rosters to the OHRP. designated as a sponsor-investigator by the FDA. Clinical investigators at academic medical centers who are initiating clinical studies with a lawfully marketed drug to be used in a patient population or indication not within the ofﬁcial labeling often ﬁt within this designation. Unlike a commercial sponsor initiating studies with an unapproved drug, often at multiple sites, a sponsor. The sponsor-investigator has submitted the protocol to FDA for its review; and; The protocol has been approved by the Institutional Review Board (IRB) with responsibility for review and approval of the protocol in accordance with the requirements of 21CFR56. The sponsor-investigator may comply with these two conditions in either order. If the.
This policy promotes compliance with FDA regulations in sponsor-investigator initiated drug, device and biologics studies at the University of Minnesota. The FDA will not directly communicate with the University regarding a sponsor-investigator's pre-submission, IND or IDE interactions. The University, however, is potentially liable for the actions of its faculty members. The requirement for. Sponsor/Sponsor‐Investigator Drug Safety Reporting Responsibilities AND Changes to Policy on Investigator Safety Information Reporting to IRB Kris West, J.D., M.S. Office of Research Compliance July 2012. What Changed? • FDA Regulations regarding IND safety reports from Sponsors/Sponsor‐Investigators to FDA. • IRB Policy on Investigator reporting of safety information to IRB - change. ICH GCP - . ICH GCP. 4.1 Qualifikation des Prüfers und Prüfvereinbarungen. 4.1.1 Ein Prüfer sollte durch Aus- und Weiterbildung sowie berufliche Erfahrung entsprechend qualifiziert sein, um die Verantwortung für die Durchführung der klinischen Prüfung zu übernehmen. Er sollte alle Qualifikationen, die durch die geltenden gesetzlichen Bestimmungen gefordert werden, vorweisen und sie. FDA Regulatory Binder and PI Responsibility Requirements. The following checklist details the investigator responsibilities outlined in the FDA Code of Federal Regulations 21 CFR 312 (drugs/biologics) and 812 (devices). The purpose of this checklist is to clarify which documents are needed to provide evidence that the investigator has fulfilled his or her responsibilities in conducting a.
FDA Inspections, 483's & Warning Letters How to Avoid and Survive Them Elizabeth L. Hohmann MD Physician Director, Partners IRBs Sarah A. White MPH Director, Partners QI Program June 12, 2017 1. Outline • Overview • FDA Inspection Process • Case Studies from FDA 483s & Warning Letters -Clinical Investigators -IRBs 2. FDA Authority • Authority derived from 21 CFR 312, 812. . Signature: _____ Date:_____ *Generally Recognized as Safe by FDA. University of Minnesota IDE Sponsor or Sponsor-Investigator . Registration Checklist and Self-Assessment . Report Date Page 3. Complete if you are a Sponsor. SPONSOR RESPONSIBILITIES. *Sponsor-Investigator is the individual who initiates and also conducts the study/clinical investigation. Typically this is the Principal Investigator (PI). A sponsor-investigator must comply with regulatory requirements applicable to both sponsors and clinical investigators (21 CFR312.3). A device will fall under the FDA regulations if data will be submitted to the FDA OR safety and/or. •Sponsor-Investigator Responsibilities •Application process to FDA •IRB Submission and Requirements 2. FDA Regulation Food and Drug Administration (FDA) regulates the approval process and assures the safety, efficacy, and security of drugs, biological products, medical devices. •Center for Drug Evaluation and Research (CDER) -21 CFR 312 •Center for Biologics Evaluation and Research. This is a training module required by Duke University for all faculty who will hold an IND or IDE and are thus considered a sponsor or sponsor-investigator. It provides information regarding the sponsor and investigator requirements for an IND or IDE as well as resources to ensure compliance with FDA regulations. This training takes approximately 1 hour and is completed online in Duke.
When the sponsor-investigator holds the IND for an investigational drug he or she is responsible for annual reporting of which of the following to the FDA? IND report. Who is responsible for making the initial rest a termination for a device being used in a study? The sponsor - investigator . THIS SET IS OFTEN IN FOLDERS WITH... Detecting and Evaluating Adverse Events Quiz. 7 terms. Elijah. Sponsor-Investigator ITP Templates NIH FDA Protocol Template ReGARDD.org Resources The ReGARDD website is a collaboration between the regulatory affairs specialists from the North Carolina CTSA Institutions and is comprised of helpful tools, templates, decision trees, and educational resources to support academic investigators' regulatory needs. ReGARDD Website ReGARDD Flyer TEAMSS. The FDA requires the sponsor/investigator either to supply a supplement to an existing IDE justifying the compassionate use or to request a new IDE. Note: Compassionate use requires FDA review and IRB approval before treatment can be initiated. The study involving the existing IDE must already be approved by the IRB. See the Emergency Use and Compassionate Use of Experimental Drugs and Devices. Sponsor Investigator Requirements - Geisinger IDE - 2-22-18 Page 1 . Guidance - Sponsor-Investigator Research Requirements both the IRB and FDA and has adequate policies and procedures in place to comply with the FDA regulatory requirements. This could include how the device is dispensed, stored, and tracked. Definitions. Sponsor-Investigator: An individu al who both initi tes nd actu.
FDA's guidance goes on to explains the basics of 21 CFR 312—the federal regulation governing IND submissions. For example, FDA provides an overview of the essential elements of an IND submission, including information about the sponsor, a summary of the investigational drug product and its risks, the clinical trial protocol and a summary of previous clinical trial results involving the drug. (a) If FDA has information indicating that an investigator (including a sponsor-investigator) has repeatedly or deliberately failed to comply with the requirements of this part, part 50 or part 56 of this chapter, or has repeatedly or deliberately submitted to FDA or to the sponsor false information in any required report, the Center for Drug Evaluation and Research or the Center for Biologics.
Sponsor-Investigator Training. A Principal Investigator who holds an FDA IND or IDE is taking on the role of Sponsor as well as the role of Investigator and is often called a Sponsor-Investigator. Because it is essential that individuals taking on this role understand their Sponsor responsibilities, the Human Research Protection Program (HRPP) requires training on Sponsor-Investigator. FDA posted a warning letter this week to a Sponsor-Investigator. Dr. Kang was warned for: Failing to follow the investigation plan, specifically Enrolling five subjects that did not meet protocol inclusion criteria (a 5 letter loss on a ETDRS visual test) Enrolling a subject without a r Sponsor-Investigator Cited for Unapproved Device Trial May 11, 2007 A physician who started an investigator-initiated trial of a significant-risk implanted device failed to get FDA approval before starting the study and did not get signed agreements for himself and the other physicians working as subinvestigators, according to a recent warning letter from the FDA PM-408 Responsibilities of the Sponsor-Investigator (IND Holder) PM-409 Regulatory Binder Management . PM-402 Conducting PI-Initiated Multi-center Trials at DF/HCC . Responsible Personnel: Overall PI, Research Nurse, Study Coordinator (CRC/CRA), Regulatory Affairs Coordinator (RAC) Policy Statement: A Form FDA 1572 (hereby referred to as the 1572 form) is required to document information.
Sponsor-Investigator: Responsibility. Process in Place (Y/N) Comments. Process to ensure appropriate IDE application submission to FDA. 21 CFR Part 812.20, 812.25, 812.27. ICH GCP E6 5.10. Do you intend to use a significant risk device in an investigation? Did you include three copies of a signed Application for an Investigational Device Exemption (IDE application)? Does your clinical.
The Sponsor-Investigator must have the necessary qualifications and resources to conduct the research and must be selected on the basis of such qualifications and resources, not for improper purposes; Payments to individual HCPs are not permitted. Proposals are evaluated according to their scientific merit, alignment with our areas of research interest, and available funding. Grant provision. FDA Requirements . A sponsor-investigator assumes all sponsor responsibilities required by the FDA as well as the investigator responsibilities, including those related to record keeping and prompt reporting of safety reports to the FDA. The responsibilities include: Selection of research staff qualified by training and experience . Commitment to personally conduct or supervise the. Sponsor-Investigator Responsibilities Our IST investigators are responsible for all aspects of trial conduct. This includes: • Design and conduct of the study protocol • Regulatory authority (such as FDA) approvals/IND filings • Safety reporting and updates to regulatory authorities and Seattle Genetics • IRB obligation
Sponsor-Investigator - An individual who both initiates and conducts an investigation and under whose immediate direction the investigational drug is administered or dispensed FDA's Clinical Investigator Training Course 2018. 8 An IND is needed when •Research involves a drug •Research is a clinical investigation •Clinical Investigation is not exempt from IND regulations -Possible. • A sponsor/sponsor-investigator can reach out to the FDA about their proposed study (prior to submitting an IND application) by scheduling a Pre-IND Meeting • This might be advantageous in cases when: • They are unsure if their study would need to be under an IND • The Sponsor would like prescriptive feedback from the FDA they can incorporate into the proposed protocol • There is a. Who. The FDA defines a sponsor-investigator as an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. The term does not include any person other than an individual. (CFR 21 312.30 (b))How. The sponsor-investigator must comply with FDA regulations applicable to both a sponsor and investigator
3. The IND Sponsor-Investigator files the .PDF and the third photocopy of the signed submission. The IND Sponsor-Investigator's photocopy is kept in an IND Binder. 45. The FDA responds to the initial submission of a new IND with a letter, acknowledging receipt of the submission and assigning the IND number. An IND generally goes into effect. But FDA recognizes that a sponsor-investigator may not have access to complete safety databut sponsor-investigators are responsible for evaluating all safety information available to them To protect human subjects, we recommend that entities that provide drug to or receive drug from other entities share safety information with each other. Editorial Comment: Reading through the.
(sponsor-investigator) Check your understanding. An investigator from Cancer Center wants to study an FDA approved drug in the new clinical trial. The investigator wrote the protocol, and a company provided the drug at no cost. Who is Regulatory Sponsor? Who is Financial Sponsor? Pharmaceutical Product Development Stages. Discovery Development Commercialization. Basic Research Pre. Clinical. FDA regulations require that sponsors make the causality assessment, based on information received from investigators; and indicates that the sponsor should consider both the investigator's and the sponsor's assessment when determining if an event is serious. Unexpected adverse event or unexpected suspected adverse reaction is an event that: It is not listed in the investigator brochure. Covers how to determine whether an investigational new drug (IND) application is required, the role of the sponsor-investigator, documentation required for INDs, and reports that must be submitted to the FDA for active INDs. Also includes information on the additional responsibilities that sponsor-investigators assume in their dual role Sponsor-Investigator Responsibilities . What is trial registration? Is it required and who is responsible for registering? As a condition of publication, the International Committee of Medical Journal Editors (ICMJE) requires study registration prior to enrolling the first subject(s)
A sponsor shall, upon request by a reviewing IRB or FDA, provide accurate, complete, and current information about any aspect of the investigation. Sec. 812.7 Prohibition of promotion and other practices. A sponsor, investigator, or any person acting for or on behalf of a sponsor or investigator shall not FDA Oversight of Tobacco Product Investigations- ITP or IND? Best Practices for the Preparation, Submission and Maintenance of Sponsor-Investigator INDs and IDEs. The IND Workshop: Kristen Foss, PhD, RAC and Stephanie Pierce, PhD June 13, 2017: Webcast. The IDE Workshop: Sarah Gemberling, PhD, RAC and Kelly Lindblom, PhD June 14, 2017: Webcast ReGARDD Medical Device Seminars Tips for. FDA ICH-GCP E6 (R2) OPERATIONAL GUIDELINE REQUIREMENTS A Curriculum for Sponsors, CROs, and Investigative Sites© Published on June 8, 2020 June 8, 2020 • 11 Likes • 3 Comment Sponsor-Investigator (SI) FDA Inspections Christiana Provencal, M. A. Quality Assurance / Quality Improvement Administrator April 13, 2018 . Inspection types • Inspection assignments are issued by the FDA Center to the District Office. There are two types of inspections: Routine/Surveillance The purpose may be to verify data submitted to the FDA or the FDA may be generally interested in what.
However, if an IRB determines the study is significant risk, the sponsor or sponsor-investigator must notify the FDA in writing. The study may not begin until the FDA approves the study or provides an NSR determination. Pre-IDE Process. Sponsors of an SR study are encouraged to review the Contact FDA - Device Guidance to obtain further guidance prior to the submission of an IDE application. The IND Sponsor-Investigator completes, signs, and dates the Form FDA 1571. The IND Sponsor-Investigator assembles the signed submission and makes three photocopies and one PDF of the original documents. *Please Note: Academic Institutions are not required to submit electronically. However, if you would like to submit electronically, please see the following contacts and guidance. Questions. Administration (FDA) requirements as well as UCLA requirements when using unapproved drugs or biologics in clinical research and an in treatment. Food and Drug Administration (FDA) regulations . 21 CFR 312 contain procedures and requirements governing the use of unapproved drugs and biologics. All clinical research projects or treatments involving drugs or biologics which are not FDA-approved.
Investigational Drugs and Devices (IND/IDE) As defined by the Food and Drug Administration (FDA), an IND, or investigational new drug application, is a request for authorization from the FDA to administer an investigational drug or biological product to humans.An IDE, or investigational device exemption, allows an investigational device to be used in a clinical study to collect safety and. The sponsor-investigator must explain to the IRB why the device does not pose a significant risk. If the IRB agrees with the non-significant risk determination, the FDA considers the device to have an approved IDE. However, if the IRB determines that the device poses a significant risk to subjects, the sponsor-investigator must notify the FDA within five working days. Sponsor-investigators. sponsor‐investigator wants the FDA to comment on the submission, the amendment must include a request for an FDA reply (e.g., a specific request to review new information and respond by a certain. These devices are then referred to as FDA registered or FDA listed devices once they make it to the market. If an exemption is not appropriate, the device is low to moderate risk, and there is a device predicate already on the market, the 510(k) pathway is then utilized. A company must prove how the new device is equivalent to the marketed device and provide pre-clinical data, but.
Ensuring Compliance with FDA medical device regulations ; Once a determination is made that an IVD is subject to FDA regulations, and does not meet the IDE exemption criteria, the Sponsor-Investigator (U-M PI in these situations) must comply with the applicable FDA regulations (21 CFR 50, 56, 812, etc.) This information is intended to prepare investigators for meeting the requirements of the FDA and IRB. This information is for guidance only and should not be viewed as a comprehensive list of requirements. It is the responsibility of each investigator to ensure that all requirements for the FDA and IRB are met. Please contact the IRB (801.581.3655) if you have any questions regarding this.
for Expanded Access. October 1, 2020. This document describes the definitions for registration data elements submitted to ClinicalTrials.gov for expanded access records. Such records provide information about investigational products that are made available through expanded access for patients who do not qualify for enrollment in a clinical trial The Sponsor-Investigator remains responsible for the research. If all goes well the investigator publishes the results which can then be used by the manufacturer. Depending on how contracts are set up, the manufacturer may also obtain anonymized datasets, original study protocol and reports among other documents. The manufacturer may also audit parts of the study. The main advantage of IIS. FORM FDA 1571 SUPPLEMENT (7/13) - FORM INSTRUCTIONS Page 2 of 5 . Field 12. SUBMISSIONS REQUIRING A JUSTIFICATION STATEMENT Select the following only if applicable. A justification statement must be submitted with the application for any items selected. Refer to the cited CFR section for further information. Expanded Access Use, 21 CFR 312.300: Note that Treatment INDs and Treatment. The sponsor/investigator has to fulfil (or agree to) the following requirements. have the scientific, technical and operational capabilities to conduct a study as a sponsor including adequately trained staff to execute a study (GCP, GMP, etc.) have expert statistical support; submit a scientifically well designed and well-written study proposal ; deliver to agreed timelines; be able to fulfill. FDA resource for E6 r2 addendum (also included in course) Good Clinical Practice Resource Guide. Division of Microbiology and Infectious Diseases December 2015. WHO ICH GCP Handbook . WHO Library Cataloguing-in-Publication Data Handbook for good clinical research practice (GCP): Guidance for implementation. ICH GCP Jobs. Linkedin Resource of ICH GCP related jobs and roles. GCP Network. Latest.